ESMO Breast 2025 | KEYNOTE-756: pembrolizumab & neoadjuvant chemotherapy in ER+/HER2- breast cancer
Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, discusses the Phase III KEYNOTE-756 study (NCT03725059) of pembrolizumab with neoadjuvant chemotherapy in patients with high-risk, early-stage ER+/HER2- breast cancer. The addition of pembrolizumab significantly improved pathological complete response compared to chemotherapy alone. Safety findings aligned with known profiles of the individual agents. While event-free survival data remain immature, the early results suggest a potential role for immunotherapy in this patient population, warranting further follow-up to assess long-term outcomes. This interview took place at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
